Axon Enterprise (NASDAQ:AXON) Price Target Raised to $550.00

Axon Enterprise (NASDAQ:AXON) had its price objective upped by Northland Securities from $365.00 to $550.00 in a report issued on Monday morning,Benzinga reports. Northland Securities currently has an outperform rating on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the company. Robert W. Baird raised their price objective on Axon Enterprise from $440.00 to $460.00 and gave the stock an “outperform” rating in a research note on Monday, November 4th. The Goldman Sachs Group lifted their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Bank of America began coverage on shares of Axon Enterprise in a research note on Wednesday, July 17th. They set a “buy” rating and a $380.00 price objective on the stock. Craig Hallum lifted their target price on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Finally, Needham & Company LLC upped their target price on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a report on Friday, November 8th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $427.83.

Axon Enterprise Trading Up 1.0 %

Shares of NASDAQ AXON opened at $601.29 on Monday. The stock has a market capitalization of $45.85 billion, a P/E ratio of 155.37, a PEG ratio of 14.95 and a beta of 0.94. The stock’s 50 day moving average price is $428.90 and its two-hundred day moving average price is $353.54. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise has a 52-week low of $220.51 and a 52-week high of $624.84.

Insider Buying and Selling at Axon Enterprise

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total value of $167,863.50. Following the completion of the transaction, the director now owns 7,379 shares of the company’s stock, valued at approximately $2,752,588.37. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Patrick W. Smith sold 70,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $362.21, for a total transaction of $25,354,700.00. Following the sale, the chief executive officer now owns 2,945,366 shares of the company’s stock, valued at $1,066,841,018.86. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $373.03, for a total value of $167,863.50. Following the transaction, the director now directly owns 7,379 shares of the company’s stock, valued at approximately $2,752,588.37. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 389,172 shares of company stock valued at $148,393,842 in the last quarter. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Axon Enterprise

Hedge funds and other institutional investors have recently modified their holdings of the company. Avantax Advisory Services Inc. grew its holdings in Axon Enterprise by 0.8% during the first quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after acquiring an additional 40 shares during the period. Foundations Investment Advisors LLC acquired a new position in shares of Axon Enterprise in the 3rd quarter worth approximately $221,000. Sequoia Financial Advisors LLC raised its holdings in shares of Axon Enterprise by 4.9% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,727 shares of the biotechnology company’s stock worth $690,000 after purchasing an additional 81 shares in the last quarter. Jag Capital Management LLC lifted its stake in Axon Enterprise by 9.7% during the third quarter. Jag Capital Management LLC now owns 56,086 shares of the biotechnology company’s stock valued at $22,412,000 after purchasing an additional 4,954 shares during the last quarter. Finally, Axxcess Wealth Management LLC bought a new stake in Axon Enterprise during the third quarter worth approximately $814,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.